Revolution Medicines (RVMD) Return on Capital Employed (2020 - 2026)
Revolution Medicines' (RVMD) quarterly Return on Capital Employed came in at 68.84% in Q1 2026, down 3457.0% year-on-year from 2.05% in Q1 2025, and down 17.19% quarter-over-quarter from 58.74% in Q4 2025.
Revolution Medicines (RVMD) Return on Capital Employed (2020 - 2026) Analysis & Trends
Revolution Medicines' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 68.84% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 3457.0% year-over-year to 68.84% in Q1 2026; TTM through Mar 2026 was 68.84%, a 3457.0% decrease from a year earlier, with the FY2025 full-year figure at 54.59%, down 2246.0% from the prior year.
- Return on Capital Employed fell to 68.84% in Q1 2026 per RVMD's latest filing, from 58.74% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 29.23% in Q1 2024 and bottomed at 81.79% in Q3 2024.
- The 5-year median for Return on Capital Employed is 38.03% (2022), against an average of 43.88%.
- Across the five-year window, Return on Capital Employed sank 4269 bps in 2024 and soared 3230 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 34.12% in 2022, then retreated by 4 bps to 35.33% in 2023, then advanced by 2 bps to 34.53% in 2024, then sank by 70 bps to 58.74% in 2025, then declined by 17 bps to 68.84% in 2026.
- Per Business Quant, the three latest RVMD Return on Capital Employed figures stand at 68.84% (Q1 2026), 58.74% (Q4 2025), and 49.5% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 20.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.84% |
| Dec 31, 2025 | -58.74% |
| Sep 30, 2025 | -49.50% |
| Jun 30, 2025 | -40.56% |
| Mar 31, 2025 | -34.27% |
| Dec 31, 2024 | -34.53% |
| Sep 30, 2024 | -81.79% |
| Jun 30, 2024 | -68.51% |
| Mar 31, 2024 | -29.23% |
| Dec 31, 2023 | -35.33% |
| Sep 30, 2023 | -39.10% |
| Jun 30, 2023 | -32.37% |
| Mar 31, 2023 | -31.02% |
| Dec 31, 2022 | -34.12% |
| Sep 30, 2022 | -38.03% |
| Jun 30, 2022 | -38.05% |
| Mar 31, 2022 | -31.94% |
| Dec 31, 2021 | -27.81% |
| Sep 30, 2021 | -24.08% |
| Jun 30, 2021 | -19.22% |